Actavis’ Record-Breaking Quarterly Sales Show Success Of Merger Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong quarter for generic Mycardis, Lidoderm and Cymbalta spurs 36% increase in pharma product sales, while businesses inherited from Warner Chilcott lead to exponential growth in North American branded product revenue. Firm is getting ready for integration of Forest around mid-year.
You may also be interested in...
Watson Begins Anew As Actavis, Focuses On Organic Growth
The traditionally generic-heavy company now has an expanded global presence and a growing branded business to go with its new name.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.